TG Therapeutics, Inc. has grown revenue 222% a year over three years and 219% a year over five. Revenue growth, 3-year annual rate: +222% (Biotechnology median +17%). Revenue growth, 5-year rate: +219%, growth has picked up over the last three years. Years of annual history on file: 25, FY2001 to FY2025, as filed.

TGTXTG Therapeutics, Inc.

Healthcare

$55.37+71% 1Y

$55.37

$26.9452 weeks$58.12

Is it growing?

Good

Growing: revenue growing +76% year on year and earnings up +643% year on year.

2 good, 1 neutral

Revenue trend+76% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +219% a year.

Earnings trend+643% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−1.0 points operating

Trailing-twelve-month operating margin, 17.6% now against 18.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TGTX growing?

TG Therapeutics, Inc. has grown revenue 222% a year over three years and 219% a year over five.

+222%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +219%
Revenue growth, 5-year rate · +222% over three · growth has picked up over the last three years
Years of annual history on file: 25
Years of annual history on file · FY2001 to FY2025, as filed

Details›